Overview {#s1}
========

Metabolic syndrome is a growing epidemic affecting \~20% of adults (over a billion people) ([@B65]; [@B73]). This complex, multifactorial disorder arising from metabolic disturbances is characterized by visceral obesity, dyslipidemia, hyperglycemia and hypertension ([@B34]). Another characteristic of metabolic syndrome is chronic low-grade inflammation ([@B18]; [@B80]). These factors all contribute to the elevated risk of cardiovascular disease, acute cardiovascular events (including stroke and myocardial infarction), type 2 diabetes mellitus (T2DM), or further complications such as renal disease ([@B65]; [@B93]). Vascular dysfunction is a key contributor to the pathogenesis of all of these disorders ([@B72]). Metabolic syndrome not only causes social and economic burdens, but significantly impacts morbidity and mortality. This review will describe how metabolic syndrome affects the regulation of vascular function and tone. Specifically, we will focus on rodent models of metabolic syndrome, highlighting the changes that occur to endothelial function and adipose tissue and consider relevance to clinical translation in humans. We will also discuss potential areas for further research to advance knowledge on vascular pathophysiology in metabolic syndrome.

Current Rodent Models for Metabolic Syndrome {#s1_1}
--------------------------------------------

An ideal translational animal model for metabolic syndrome would closely resemble the human anatomy and pathophysiology of the disease ([@B22]). Thus, an important consideration when choosing an animal model is that it mimics the key clinical criteria that define metabolic syndrome. The International Diabetes Federation defines metabolic syndrome as central obesity and at least two of the following: dyslipidemia (\>150 mg/dl plasma triglycerides and/or reduced high-density lipoproteins (HDL) \< 40 mg/dl for men and \<50 mg/dl for women), elevated blood pressure (≥130 mmHg systolic and/or ≥ 85 mmHg diastolic), or hyperglycemia (≥100 mg/dl fasting plasma glucose) ([@B2]). Importantly, many patients do not present with all of these classifications, and similarly there is no one animal model that mimics all of these abnormalities of metabolic syndrome.

### Genetic Mouse Models {#s1_1_1}

Genetic models of obesity and diabetes allow for the evaluation of specific molecular mechanisms. C57BL/6J-*Lep^ob^* mice, more commonly known as *ob/ob* mice, were one of the first genetic models of obesity. These mice lack leptin due to a spontaneous homozygous mutation on the leptin gene, causing marked obesity, hyperinsulinemia, and hyperglycemia by 12 weeks of age. By approximately 24 weeks of age, *ob/ob* mice develop left ventricular hypertrophy and cardiac fibrosis and are in a pro-inflammatory state ([@B49]). The C57BL/KsJ-db/db (*db/db*) mouse is a related genetic mouse model, which has a defective leptin receptor ([@B98]). By 13 weeks of age, *db/db* mice are overweight and have hyperglycemia and dyslipidemia (increased plasma triglycerides, total cholesterol, and non-esterified fatty acids). Importantly, endothelium-dependent aortic relaxation to acetylcholine (ACh) is impaired whereas that to direct nitric oxide donors remains unaffected, indicating endothelial dysfunction ([@B20]). Additionally, *db/db* mice have elevated circulating leptin which promotes a pro-inflammatory state, linked to the increased activity of interleukin-6 (IL-6) ([@B49]). Neither *ob/ob* nor *db/db* mice, however, display increased blood pressure---unlike a large proportion of humans with metabolic syndrome---and are therefore not ideal models for the many such people with metabolic syndrome ([@B58]).

### Genetic Rat Models {#s1_1_2}

Zucker Fatty rats are among the most common genetic rat models of metabolic syndrome and are deficient in the leptin receptor due to a missense mutation in the gene. This increases circulating leptin levels and rats are obese by 3--5 weeks of age ([@B3]). These rats variably develop hyperglycemia (the severity is variable between studies, and sometimes within the same cohort), dyslipidemia, and hypertension ([@B114]; [@B59]; [@B110]; [@B99]; [@B106]). However, several studies also report conflicting data, with lower systolic blood pressure in Zucker fatty rats compared to the lean controls ([@B3]). Thus, while in some studies the model does appear to accurately reflect the presentation of metabolic syndrome patients in the clinic, inconsistencies between different studies make it difficult to develop definitive conclusions.

The Dahl salt-sensitive rat is widely used to study salt-induced hypertension and, when crossed with Zucker fatty rats, the resulting offspring are DahlS.Z-Lepr^fa^/Lepr^fa^ (DS/obese) rats. DS/obese rats have hyperphagia and develop abdominal obesity, hypertension, dyslipidemia, and T2DM and thus, appear to be a useful model for advanced metabolic syndrome ([@B38]). Obese spontaneously hypertensive rats (also known as Koletsky rats) are another animal model used to study metabolic syndrome. These rats are obese by 5 weeks of age and develop hyperlipidemia even when fed a normal chow diet. Mild hyperinsulinemia is present with only slight hyperglycemia. At 3 months of age, spontaneous hypertension occurs with mean arterial pressure rising to ≥180 mmHg ([@B3]).

### Diet-Induced Rodent Models {#s1_1_3}

Diet modifications are often used to study metabolic syndrome due to pronounced effects on metabolism and in turn, hormonal, glucose, and lipid pathways. Fructose-enriched diets are effective for inducing metabolic syndrome and act *via* several mechanisms to promote obesity ([@B45]). Mechanisms relevant to the satiety center suggest that fructose stimulates the production of insulin and leptin but inhibits ghrelin ([@B91]). Other studies suggest that the addition of fructose simply makes food more appetizing and stimulates increased food intake and weight gain ([@B55]). Simple and complex carbohydrates are essential nutrients and the main source of energy for the body. Adopting a sedentary lifestyle in conjunction with excessive carbohydrate consumption can result in an imbalance in energy, which increases blood glucose and increases release of insulin. This imbalance predisposes individuals to weight gain and decreases insulin sensitivity ([@B106]).

A high fat diet (HFD) can also be used to induce metabolic syndrome. Mice fed a HFD from 4 to 6 weeks of age develop obesity, hyperglycemia, and endothelial dysfunction after 10 weeks ([@B47]; [@B53]). In some instances, systolic blood pressure is mildly raised (by \~10 mmHg), suggesting a pre-hypertensive state ([@B90]). HFD mice have increased quantities of white adipose tissue, which enhances the expression of pro-inflammatory mediators such as tumor necrosis factor alpha (TNF-α). This mechanism is thought to be a key driver for insulin resistance in obesity ([@B56]). To date, numerous types of HFD regimens have been used, with variations in the amount of fat (20 to 60% of total energy) and its source (lard, beef tallow, olive, or coconut oil) as well as the duration of feeding and age of animals. The fat source appears to be particularly important. Fats derived from lard, coconut and olive oil increase body weight, plasma insulin and triglyceride and decrease plasma adiponectin concentrations in male Wistar rats ([@B13]). Alternatively, beef tallow derived-fat increases plasma leptin, insulin, and lipid concentrations ([@B42]).

HFD rodent models display most of the features of metabolic syndrome, but patients with metabolic syndrome would typically consume a higher proportion of simple carbohydrates than most HFD models in the literature ([@B69]). Diets comprising both high fat and high carbohydrate components promote even more of the features of metabolic syndrome in rodents and are therefore more clinically representative than just HFD alone ([@B69]). One potential criticism of these diet-induced models is that they rarely lead to atherosclerosis. Thus, HFD regimens are often combined with mice that are genetically dyslipidemic to incorporate the atherosclerotic phenotype in metabolic syndrome. For example, apolipoprotein E-deficient (*ApoE^−/−^*) mice and low density lipoprotein receptor deficient (*LDLR^−/−^*) mice show similar metabolic profiles to the diet-induced models described above, but have the added complication of advanced atherosclerosis ([@B22]).

Despite there being a variety of rodent models of metabolic syndrome available (summarized in [**Table 1**](#T1){ref-type="table"}), the precise mechanisms behind the progression to a diseased vascular state remain poorly understood. Obesity and the abnormalities associated with metabolic syndrome (i.e., hypertension, dyslipidemia, hyperglycemia) adversely impact vascular structure and function ([@B10]). The remainder of this review will address this.

###### 

Summary of different rodent models of metabolic syndrome and their effects on varying vessels.

  Model                                                                       Age            Species                           Sex       Vessel     Effect of metabolic syndrome                                                                                                                                 Ref
  --------------------------------------------------------------------------- -------------- --------------------------------- --------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------
  HFD (45% kcal from fat) for 32 weeks                                        37 weeks       C57BL/6J mice                     M         MA         ↑ Superoxide and NOX activity in PVAT                                                                                                                        ([@B32])
  WD (30% fructose, 20% lard, 18% protein, 5% cellulose) for 42 weeks         50 weeks       Sprague-Dawley rats               M         TA         ↑ROCK pathway associated with insulin resistance                                                                                                             ([@B21])
  High carbohydrate, HFD (% kcal from fat + 15% fructose in drinking water)   24 weeks       Sprague-Dawley rats               M         CA, MA     ↑Insulin sensitivity and lipid profiles; ↓SBP                                                                                                                ([@B78])
  HFD (59% kcal from fat) for 16 weeks                                        24 weeks       Swiss mice                        F         Aorta      ↑ SBP and DBP; ↓ aortic relaxation to ACh but not SNP; ⟷ aortic IL-1β and IL-6 protein expression; ↓ aortic NF-kB                                            ([@B47])
  HFD (42% kcal from fat) for 30 weeks                                        35 weeks       C57BL/6J mice                     M         TA, CA     ↑Prostanoids and vascular thromboxane receptor gene expression                                                                                               ([@B92])
  C57BL/6J-*Lep^ob^ (ob/ob)*                                                  27--32 weeks   C57BL/6J mice                     M         Aorta MA   ↑Plasma insulin, PKC activity, GRK2 protein levels; ↓aortic insulin-induced relaxation, ACh-induced relaxation                                               ([@B104]; [@B86])
  C57BL/KsJ-db/db (*db/db*)                                                   16 weeks       C57BL/KsJ mice                    M         MA         ↑Production of superoxide anions; ↓ACh-induced relaxation and BH~4~ bioavailability                                                                          ([@B71])
  Zucker diabetic fatty (ZDF *fa/fa*) rat                                     9--11 weeks    Zucker diabetic fatty rats        M         Aorta      ↑FFA-induced NADPH oxidase activation and ROS production                                                                                                     ([@B15])
  Spontaneously hypertensive rats                                             14 months      Spontaneously hypertensive rats   M         TA         ↑ROS formation, NADPH oxidase activity and protein expression of NOX 1 and NOX 2; ↓ACh-induced relaxation                                                    ([@B103])
  HFD (20.5% protein, 35.7% carbohydrates, and 36.0% fat)                     24--28 weeks   Dahl-Salt Sensitive rats          F and M   Aorta      ↑HFD male and female SBP at 4 weeks and CD4+ T cells and T helper cells, greater CD3+ T cells in males, and greater % of pro-inflammatory T cells in males   ([@B90])

ACh, acetylcholine; BH~4~, tetrahydrobiopterin; CA, carotid arteries; DBP, diastolic blood pressure; F, female; FFA, free fatty acid; GRK2, G protein-coupled receptor kinase 2; HFD, high fat diet; IL, interleukin; Kcal, kilocalorie; M, male; MA, mesenteric arteries; NF-kB, nuclear factor kappa beta; NOX, NADPH oxidase; PKC, protein kinase C; PVAT, perivascular adipose tissue; ROCK, Rho kinase; SBP, systolic blood pressure; SNP, sodium nitroprusside; TA, thoracic aorta; WD, western diet.

The Role of Metabolic Syndrome Comorbidities on Endothelial Dysfunction {#s1_2}
-----------------------------------------------------------------------

Endothelial dysfunction predisposes the vasculature to a heightened contractile state due to an imbalance between endothelium-derived relaxing (e.g., NO, PGI~2~, EDH downregulation) and contracting factors (e.g., TxA~2~, ET-1 upregulation) ([@B35]; [@B51]). Endothelial dysfunction also promotes pro-inflammatory and oxidative stress pathways *via* endothelial mitochondrial reactive oxygen species (ROS) driving vascular growth and remodeling ([@B14]; [@B81]; [@B102]). This fundamental switch of the endothelium in metabolic syndrome to a dysfunctional state, involves the host immune system and production of ROS ([@B19]), and the progression of diseases occurs *via* a variety of dynamic changes within the vasculature ([**Figure 1**](#f1){ref-type="fig"}). There are many detailed reviews regarding the function of the endothelium in a physiological state ([@B14]; [@B23]; [@B37]; [@B72]), and thus, this review will focus on the mechanisms of endothelial dysfunction that accompany the comorbidities of metabolic syndrome. Some animal models of metabolic syndrome inherently present with multiple comorbidities---for example diet-induced models may present hyperglycemia, dyslipidemia, and obesity. However, the studies mentioned in this section focus on individual comorbidities and their effect on endothelial dysfunction.

![Current therapies for the comorbidities of metabolic syndrome, targetting nitric oxide and reactive oxygen species signaling in endothelial dysfunction. Metabolic syndrome is characterized by an increase in visceral adiposity, blood pressure, glucose intolerance, and dyslipidemia. Individually, these co-morbidities induce endothelial dysfunction by increasing reactive oxygen species (ROS) and reducing nitric oxide (NO; pathways indicated in black). ROS is increased *via* increases in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and pro-inflammatory adipokines and reductions in superoxide dismutase (SOD). This reduces endothelial nitric oxide synthase (eNOS) production *via* two key mechanisms: reduced L-arginine conversion and soluble guanylate cyclase (sGC) activity. Uncoupling of eNOS occurs *via* two mechanisms \[tetrahydrobiopterin (BH~4~) and 5′-AMP-activated protein kinase (AMPK) inactivation\] to further reduce eNOS activity. Increased cyclooxygenase-2 (COX-2) activity drives the production of vasoconstrictor prostanoids (PGF~2a~, prostaglandin F2α; TXA~2~, thromboxane A2) and decreases prostacyclin (PGI~2~) production. ROS also drives the production of other endothelium-derived contracting factors (ET-1= endothelin-1, 5-HT= serotonin and PE= phenylephrine). Many first-line therapeutic drugs for the co-morbidities of metabolic syndrome (colored) target these mechanisms. Metformin (blue) reduces AMPK inactivation and peroxynitrite (ONOO-) production. Angiotensin converting enzyme (ACE) inhibitors (pink) reduce SOD activity. Statins (yellow) reduce AMPK inactivation and ROS production and increase sGC activity. Spironolactone and dipeptidyl peptidase-4 (DPP4) increase eNOS activity. Spermidine (turquoise) and vitamin D (dark yellow) inhibit the activation of pro-inflammatory adipokines released from adipose tissue, and spermidine promotes AMPK activation. BH~2~, 7,8-dihydrobiopterin; cGMP, cyclic guanosine-3′,5′-monophosphate; cGK1, cGMP-dependent protein kinase-1; ROCK, RhoA associated protein kinase; GLP1, glucagon-like peptide 1. Created with [BioRender.com](BioRender.com).](fphar-11-00148-g001){#f1}

### Hyperglycemia {#s1_2_1}

In *db/db and ob/ob* mice, endothelium-dependent vasodilatation is impaired in the coronary arterioles, aorta, and mesenteric arteries. This impairment is associated with enhanced superoxide production and the activation of immune responses downstream of the NACHT, LRR, and PYD domains-containing protein 3 inflammasome, which reduces the function of endothelium-dependent relaxing factors and the regulation of insulin ([@B7]; [@B66]; [@B94]). Endothelial dysfunction is not only a consequence of insulin resistance, but also impairs insulin signaling to further reduce insulin sensitivity, thereby resulting in a destructive cycle in metabolic syndrome and diabetes. In obese Zucker rats, altered insulin signaling disrupts insulin-mediated NO production (*via* downregulation of eNOS expression) to impair vasodilatation in resistance arteries. The involvement of ROS and subsequent degradation of BH~4~ (a cofactor essential for NO synthesis from eNOS) synthesis in insulin resistance is thought to play a role in the impairment of NO-dependent vasodilatation ([@B26]). In T2DM patients, ROS reduces the availability of BH~4~ ([@B41]). Reduced interaction between BH~4~ and eNOS leads to eNOS uncoupling and production of superoxide instead of NO ([@B41]). In that study, an infusion of BH~4~ partially counteracted the reduced ACh-induced vasodilation, demonstrating that eNOS uncoupling and reduction of NO availability contribute to endothelial dysfunction in T2DM ([@B41]). An early study using female streptozotocin (STZ)-induced diabetic rats found impaired endothelial function in mesenteric arteries due mainly to altered production of vasodilators rather than ROS ([@B88]). Endothelial dysfunction is region-specific in this model--- as endothelial impairment was absent in the aortae of the diabetic animals ([@B89]). The therapeutic potential of antioxidants has been a key area of interest in hyperglycemia research due to their ability to scavenge/neutralize ROS ([@B63]; [@B17]; [@B97]). However, large clinical studies have investigated the effects of anti-oxidant vitamins (such as vitamin E and C) in diabetes, and these did not reduce the incidence of vascular disease ([@B40]; [@B107]). Furthermore, acute hyperglycemia promotes vasoconstrictor-prostanoid production and thus, an increased vascular smooth muscle cells (VSMC) contractility and vascular tone ([@B7]; [@B66]).

There are a number of therapeutics available for the treatment of hyperglycemia. Pharmacological therapies such as thiazolidinediones, statins, and metformin not only improve insulin sensitivity, but also endothelium-dependent vasodilation in patients with type 2 diabetes ([@B70]; [@B109]; [@B107]) and in diabetic rodent studies ([@B46]; [@B105]). Metformin is the first-line drug used for the treatment of hyperglycemia. Despite this, the precise mechanisms by which metformin lowers blood glucose levels are still unclear, but AMPK activation is thought to be a key target of action ([@B25]). AMPK is also thought to be a potential target in reversing endothelial dysfunction by promoting eNOS phosphorylation to stimulate NO production ([@B17]; [@B107]). Conversely, cell-culture studies indicate that this occurs independently of AMPK activation in mouse microvascular endothelial cells, but rather *via* eNOS and Akt phosphorylation ([@B31]). Thus, the involvement of AMPK in metformin therapy may require the involvement of other cell-types. A newer therapeutic strategy for hyperglycemia is glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors. Glucagon-like peptide-1 is a direct endothelium-dependent vasodilator, and is also NOS-dependent. The vasoprotective effects of glucagon-like peptide-1 receptor agonists have been shown in a number of clinical studies too, however, there are also studies that show detrimental effects on the vasculature ([@B9]). Such detrimental effects appear to occur with chronic long-term administration (\>4 weeks), highlighting the importance of determining long-term effects of hyperglycemia medications on the vasculature.

### Dyslipidemia {#s1_2_2}

Endothelial relaxation is impaired *via* multiple pathways in dyslipidemia. In humans with hypercholesterolemia, ACh-induced vasodilatation is reduced, whereas G~i~-independent bradykinin-induced vasodilatation remains unchanged ([@B60]; [@B30]).This indicates a selective loss of some vasorelaxation pathways in hypercholesterolemia ([@B60]; [@B30]). Rodent models have been previously used to study lipid metabolism and its links to cardiovascular disease, however there are significant differences between lipid metabolism in rodents and humans. For example, mice carry the majority of plasma cholesterol in HDL, whereas humans carry it in low-density lipoproteins (LDL) ([@B33]). However, there are similarities between the species that should be noted. For the protein diversity of HDL and LDL size ranges are similar in both humans and mice, and mice have minor proteins that are identified in humans which play a role in inflammation and innate immunity ([@B33]). The majority of rodent dyslipidemia studies to date (characterized by increased triglycerides, decreased HDL and abnormal LDL) have been performed in ApoE^−/−^ mice. Interestingly, despite severe hypercholesterolemia, young ApoE^−/−^ mice have normal vascular function. Importantly, once challenged with either HFD or ageing to induce atherosclerotic lesions, relaxation (both endothelial-dependent and -independent) is impaired.

In non-rodent animal models, such as hypercholesterolemic rabbits, L-arginine treatment inhibits atherosclerosis and improves NO-mediated vasodilatation in thoracic and abdominal aortae and iliac arteries by enhanced NO synthesis and eNOS expression ([@B43]; [@B39]) The increased levels of oxidized low-density LDL in dyslipidemia has cytotoxic potential and atherogenic properties, and may also attenuate NO activity. In cultured human endothelial cells, oxidized LDL exposure decreased eNOS messenger RNA (mRNA) expression ([@B82]). In human umbilical vein endothelial cells, eNOS mRNA degradation is also linked to upregulation of the pro-inflammatory cytokine TNF-α in atherosclerotic lesions. Therefore, pro-inflammatory cytokines that interfere with eNOS mRNA levels may reduce eNOS activity and impair vasorelaxation in dyslipidemia ([@B111]). Transmembrane receptor LOX-1 can also directly mediate oxidized LDL inducing superoxide formation through the activation of nuclear factor kappa B ([@B16]; [@B74]). Not only does this contribute to lipid accumulation through macrophages and inflammatory cytokines, high levels of circulating oxidized LDL acts on receptors that decrease L-arginine availability, thus altering NO production and ultimately endothelial function ([@B76]). Statins are used in the clinic to lower blood LDL cholesterol. An added benefit of statins is that they also reverse endothelial dysfunction in dyslipidemic patients ([@B12]). Cell culture studies confirm that statins stabilize eNOS mRNA to increase NO production in human endothelial cells ([@B12]). Additionally, statins λ also reduce nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity by downregulating NOX-1 mRNA expression, thus suppressing O~2~^−^ generation in hypertensive rats further contributing to the protective effects of statins ([@B100]; [@B4]). Spermidine, a precursor to polyamines, has been shown to exert anti-inflammatory properties, and to inhibit age-related oxidative protein damage and ROS. To target lipid metabolism, spermidine induces AMPK pathway to regulate autophagy, in turn inhibiting expression of fatty acids ([@B29]).

### Obesity {#s1_2_3}

In obesity, the severity of endothelial dysfunction strongly correlates with the degree of visceral adiposity ([@B54]). This is likely to be due to multiple pathways, such as adipocyte hypertrophy, hypoxia and macrophage infiltration ([@B50]). Similar to hypertensive conditions, visceral adiposity increases oxidative stress, and promotes changes in the pro-inflammatory adipokine profile resulting in eNOS uncoupling ([@B52]). Specifically, circulating pro-inflammatory adipokines such as visfastin, apelin, retinol binding protein-4, vaspin, serum amyloid A, plasminogen activator inhibitor-1, angiotensinogen, chemerin and are increased in obesity. Conversely, obesity is associated with reduced adiponectin, omentin, and zinc-α2-glycoprotein ([@B50]). In obesity, NADPH oxidase upregulation also accentuates ROS production and induce endothelial dysfunction in the aorta ([@B79]; [@B44]). In endothelial cells, the nuclear factor-κB (NF-κB) pathway mediates inflammation by increasing ROS production and reducing NO production ([@B47]). Additionally, surrounding adipocytes secrete products that stimulate the increase of adhesion molecules and apoptosis of endothelial cells ([@B47]). Although obese patients present with elevated NF-κB expression, it is unknown whether the direct inhibition of this pathway improves endothelium-dependent relaxation ([@B83]). Weight loss is the primary objective for obese patients. In obese patients with essential hypertension, calorie restriction demonstrated beneficial effects and improvement in endothelium-dependent vasodilation stimulating an increased release of nitric oxide ([@B77]).

In diet-induced obese mice, vascular dysfunction (in the thoracic aorta and carotid artery) is associated with increased thromboxane gene expression and vasoconstrictor prostanoids ([@B92]). Non-selective COX inhibition blocks ACh-induced contraction but selective inhibition of COX-2 is without effect ([@B92]). Additionally, thromboxane synthase inhibitors did not affect ACh-induced contraction, indicating that vascular dysfunction in obesity is driven by upregulation of vascular thromboxane receptor and endothelium-dependent prostanoid vasoconstrictors ([@B92]). COX-inhibition also altered ET-1-induced contraction ([@B92]; [@B64]). This provides evidence that, not surprisingly, multiple mechanisms are involved in endothelial dysfunction in obese rodents. Importantly though, diet-induced obese mice are normotensive, indicating that obesity-induced endothelial dysfunction is likely independent of changes to blood pressure.

Epidemiological studies indicate that low vitamin D levels are associated with all of aforementioned co-morbidities of metabolic syndrome ([@B84]; [@B6]). *In vitro* studies demonstrate that vitamin D3 inhibits pre-adipocyte proliferation by downregulating adipogenesis genes ([@B113]) and reducing obesity-induced inflammation ([@B57]). Despite ample evidence that vitamin D hinders the development of adipose, the precise mechanism by which vitamin D influences obesity has not yet been elucidated.

### Hypertension {#s1_2_4}

The pathophysiology of hypertension is multifactorial and related to activation of the sympathetic nervous system, renin-angiotensin-aldosterone system, pro-inflammatory mediators, endothelial dysfunction, and increased oxidative stress ([@B67]). Sustained elevated pressure in the vasculature promotes premature ageing and increased endothelial cell turnover ([@B11]). The regenerated endothelial cells have an impaired ability to release endothelium-derived relaxing factors ([@B87]). Endothelial dysfunction has been demonstrated in most animal models of hypertension including spontaneously hypertensive rats (SHRs), angiotensin II-induced hypertension, Dahl salt-sensitive rats, and the two-kidney one-clip model ([@B85]; [@B108]; [@B61]). A sustained elevation of blood pressure is linked with decreased levels of NO and increased vascular ROS ([@B48]). Oxidative stress plays a major role in the pathophysiology of hypertension-induced endothelial dysfunction. ROS alone promote vasoconstriction and impair antioxidant production ([@B75]). Superoxide and other ROS inhibit NO bioavailability in several ways. Superoxide can react directly with NO to form peroxynitrite. This leads to eNOS uncoupling, thus aggravating the reduced NO production and promoting endothelial dysfunction ([@B8]). Peroxynitrite can also nitrate other proteins, altering their function ([@B68]). This correlates with studies in hypertensive patients reporting decreased NO availability and increased serum malondialdehyde \[a clinical indicator of elevated ROS; ([@B101]; [@B36]; [@B5])\]. Increased NADPH oxidase activity has been observed in angiotensin II-induced hypertension, deoxycorticosterone acetate-salt hypertension and SHRs. In angiotensin II-infused mice, increased ROS is linked to eNOS uncoupling, BH~4~ oxidation and further increases in superoxide, impairing endothelial function. This is also associated with downregulation of downstream targets of NO, such as cyclic-GMP, soluble guanylate cyclase, protein kinase G-dependent phosphorylation, S-nitrosylation, and transnitrosylation ([@B62]; [@B112]). Clinically, there is an abundance of pharmacological treatments for hypertension that directly target the renin angiotensin aldosterone system (incl. angiotensin converting enzyme inhibitors and angiotensin II receptor blockers). In addition to blocking renal sodium reabsorption and plasma volume expansion ([@B28]), many of these also improve endothelial dysfunction. This occurs *via* inhibition of vascular angiotensin I and II conversion and by increasing NO bioavailability ([@B27]). The precise mechanisms by which this occurs varies between the different types of drugs. Mineralocorticoid receptor antagonists such as spironolactone increases NO bioavailability *via* the upregulation of eNOS and downregulation of the proinflammatory cytokine TGF-ß ([@B1]). ACE inhibitors increase NO bioavailability *via* three key mechanisms: increased intracellular calcium to increase NO production; blocking natural endopeptidase to inhibit local bradykinin degradation; and enhancing activity of the antioxidant superoxide dismutase ([@B24]).

The transformation of arachidonic acid by cyclooxygenase results in the production of endoperoxides, releasing endothelial-derived contracting factors ([@B96]). Importantly, many rodent studies show evidence of increased vasoconstrictor prostanoid responses in hypertension ([@B96]; [@B95]). Conversely, blunted endothelium-dependent vasodilation is the key underlying cause of vascular dysfunction in hypertensive humans ([@B96]). Therefore, while the impact of hypertension on the vasculature is similar between species, the underlying mechanisms may differ. This highlights the challenge of translating pre-clinical findings to a clinical setting. Thus, identification and use of the most representative animal models of human disease are vital for progressing our understanding of these conditions.

Conclusion {#s2}
==========

Accompanying the global rise in obesity, metabolic syndrome is an escalating public health concern. Metabolic syndrome is a multifactorial disorder, and hence it is not surprising that numerous signaling pathways contribute to the subsequent endothelial dysfunction. Despite this, the majority of current therapies that treat the comorbidities of metabolic syndrome and improve endothelial dysfunction target NO and ROS signaling ([**Figure 1**](#f1){ref-type="fig"}). Future studies should investigate the effects of therapeutics which target vasoconstrictor prostanoids, another key mechanism of endothelial dysfunction in metabolic syndrome.
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